Vyvanse Pregnancy Information
Vyvanse (lisdexamfetamine) does not have a formal FDA pregnancy category, as the letter-based system (A, B, C, D, X) was discontinued in 2015. However, based on the most recent 2024 guidelines and FDA labeling, the drug carries warnings about potential fetal effects and requires careful risk-benefit assessment during pregnancy 1, 2.
Current Safety Profile
Lisdexamfetamine appears to have a reassuring safety profile regarding major congenital malformations, though limited data exist specifically for this medication. Since lisdexamfetamine is a prodrug converted to dextroamphetamine, its risk profile mirrors that of amphetamines 1.
Key Fetal and Obstetric Risks
Based on amphetamine data (applicable to Vyvanse):
- No increased risk of major congenital malformations including cardiac defects 1
- Possible small increased risk for:
Recent registry data from 2023 found no major malformations in 40 infants exposed to lisdexamfetamine in the first trimester (OR 0.39,95% CI 0.09-1.61 for any stimulant compared to controls) 3. A 2023 Danish cohort study of 898 children exposed to ADHD medications in utero found no increased risk of neurodevelopmental disorders or growth impairment (aHR 0.97,95% CI 0.81-1.17) 4.
Clinical Decision-Making
The decision to continue or discontinue Vyvanse during pregnancy must weigh maternal functional impairment against potential fetal risks. Untreated ADHD during pregnancy is associated with increased risks of spontaneous abortion and preterm birth, plus significant maternal functional impairment 1.
Important Caveats
- Limited published data specifically on lisdexamfetamine - most evidence extrapolated from amphetamine studies 1
- Stimulants cross the placenta and expose the developing fetus 1
- 77% of women discontinue stimulants before or during pregnancy, with postpartum resumption rates remaining 45% below preconception levels 5
- A 2026 study found women continuing stimulants during pregnancy had 1.2-3.1 times higher odds of prenatal maternal, placental, and birth-related complications compared to those who discontinued 6
Breastfeeding Considerations
The FDA label advises women not to breastfeed while taking Vyvanse 2. However, the 2024 AJOG guidelines assign a Hale lactation risk category of L3 (probably compatible), noting that breastfeeding does not seem to adversely affect infants when amphetamines are used therapeutically 1.
Monitor breastfed infants carefully for:
- Irritability
- Insomnia
- Feeding difficulties 1
One case report documented successful breastfeeding with lisdexamfetamine use without observed infant side effects 7.
Pregnancy Registry
A pregnancy exposure registry exists to monitor outcomes in women exposed to Vyvanse during pregnancy. Patients should be informed of this registry and encouraged to enroll 2.